This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

Corbus Pharmaceuticals has a twelve month low of $6.38 and a twelve month high of $61.90. The company has a market capitalization of $82.70 million, a price-to-earnings ratio of -1.45 and a beta ...

Corbus Pharmaceuticals has a 12 month low of $6.54 and a 12 month high of $61.90. The stock’s fifty day moving average price is $9.98 and its 200-day moving average price is $20.82.

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based ...